TY - JOUR
T1 - Surface Modification with Lactadherin Augments the Attachment of Sonazoid Microbubbles to Glycoprotein IIb/IIIa
AU - Otani, Kentaro
AU - Kamiya, Atsunori
AU - Miyazaki, Takahiro
AU - Koga, Ayumi
AU - Inatomi, Ayako
AU - Harada-Shiba, Mariko
N1 - Funding Information:
This study was supported by research grants from the Nakatani Foundation for Advancement of Measuring Technologies in Biomedical Engineering (to K.O.), the Fukuda Foundation for Medical Technology (to K.O.) and the Japan Agency for Medical Research and Development (AMED) under Grant No. JP16mk0101037 (to K.O.).
Publisher Copyright:
© 2019 World Federation for Ultrasound in Medicine & Biology
PY - 2019/6
Y1 - 2019/6
N2 - Arginine–glycine–aspartate (RGD)-carrying microbubbles (MBs) have been utilized as a specific contrast agent for glycoprotein IIb/IIIa (α IIb β 3 integrin)-expressing activated platelets in ultrasound molecular imaging. Recently, we found that surface modification with lactadherin provides the RGD motif on the surface of phosphatidylserine-containing clinically available MBs, Sonazoid. Here, we examined the potential of lactadherin-bearing Sonazoid MBs to be targeted MBs for glycoprotein IIb/IIIa using the custom-designed in vitro settings with recombinant α IIb β 3 integrin, activated platelets or erythrocyte-rich human clots. By modification of the surface with lactadherin, a large number of Sonazoid MBs were attached to the α IIb β 3 integrin-coated and platelet-immobilized plate. Additionally, the video intensity of clots after incubation with lactadherin-bearing Sonazoid MBs was significantly higher than that with unmodified Sonazoid MBs, implying the number of attached Sonazoid MBs was increased by the modification with lactadherin. Our results suggest that the lactadherin-bearing Sonazoid MBs have the potential to be thrombus-targeted MBs.
AB - Arginine–glycine–aspartate (RGD)-carrying microbubbles (MBs) have been utilized as a specific contrast agent for glycoprotein IIb/IIIa (α IIb β 3 integrin)-expressing activated platelets in ultrasound molecular imaging. Recently, we found that surface modification with lactadherin provides the RGD motif on the surface of phosphatidylserine-containing clinically available MBs, Sonazoid. Here, we examined the potential of lactadherin-bearing Sonazoid MBs to be targeted MBs for glycoprotein IIb/IIIa using the custom-designed in vitro settings with recombinant α IIb β 3 integrin, activated platelets or erythrocyte-rich human clots. By modification of the surface with lactadherin, a large number of Sonazoid MBs were attached to the α IIb β 3 integrin-coated and platelet-immobilized plate. Additionally, the video intensity of clots after incubation with lactadherin-bearing Sonazoid MBs was significantly higher than that with unmodified Sonazoid MBs, implying the number of attached Sonazoid MBs was increased by the modification with lactadherin. Our results suggest that the lactadherin-bearing Sonazoid MBs have the potential to be thrombus-targeted MBs.
KW - Glycoprotein IIb/IIIa
KW - Microbubble
KW - Platelets
KW - Thrombus
KW - Ultrasound molecular imaging
UR - http://www.scopus.com/inward/record.url?scp=85062455437&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85062455437&partnerID=8YFLogxK
U2 - 10.1016/j.ultrasmedbio.2019.01.022
DO - 10.1016/j.ultrasmedbio.2019.01.022
M3 - Article
C2 - 30857759
AN - SCOPUS:85062455437
VL - 45
SP - 1455
EP - 1465
JO - Ultrasound in Medicine and Biology
JF - Ultrasound in Medicine and Biology
SN - 0301-5629
IS - 6
ER -